Cost-effectiveness of antiretroviral therapy for multidrug-resistant HIV: Past, present, and future

AIDS Research and Treatment

Volumn 2012, Issue , 2012, Pages

  Harris, Marianne ^a,b   Nosyk, Bohdan ^c   Harrigan, Richard ^b,c   Lima, Viviane Dias ^b,c   Cohen, Calvin ^d   Montaner, Julio ^b,c  

^a PROVIDENCE HEALTH CARE RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^d Boston Community Research Initiative of New England   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873851566     PISSN: 20901240     EISSN: 20901259     Source Type: Journal    
DOI: 10.1155/2012/595762     Document Type: Review

References (77)

1. Hogg R. S., Bangsberg D. R., Lima V. D., Alexander C., Bonner S., Yip B., Wood E., Dong W. W. Y., Montaner J. S. G., Harrigan P. R., Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Medicine 2006 3 9 1570 1578 2-s2.0-33749021387 10.1371/journal.pmed.0030356 (Pubitemid 44455267)
2. Richman D. D., Morton S. C., Wrin T., Hellmann N., Berry S., Shapiro M. F., Bozzette S. A., The prevalence of antiretroviral drug resistance in the United States. AIDS 2004 18 10 1393 1401 2-s2.0-3142660152 10.1097/01.aids. 0000131310.52526.c7 (Pubitemid 38925131)
3. Lima V. D., Harrigan P. R., Sénécal M., Yip B., Druyts E., Hogg R. S., Montaner J. S. G., Epidemiology of antiretroviral multiclass resistance. American Journal of Epidemiology 2010 172 4 460 468 2-s2.0-77955873085 10.1093/aje/kwq101
4. Gulick R. M., Mellors J. W., Havlir D., Eron J. J., Gonzalez C., McMahon D., Richman D. D., Valentine F. T., Jonas L., Meibohm A., Emini E. A., Chodakewitz J. A., Deutsch P., Holder D., Schleif W. A., Condra J. H., Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. The New England Journal of Medicine 1997 337 11 734 739 2-s2.0-0030869269 10.1056/NEJM199709113371102 (Pubitemid 27417972)
5. Montaner J. S. G., Reiss P., Cooper D., Vella S., Harris M., Conway B., Wainberg M. A., Smith D., Robinson P., Hall D., Myers M., Lange J. M. A., A randomized double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA 1998 279 12 930 937 2-s2.0-0032565098 10.1001/jama.279.12.930 (Pubitemid 28136082)
6. Cameron D. W., Japour A. J., Xu Y., Hsu A., Mellors J., Farthing C., Cohen C., Poretz D., Markowitz M., Follansbee S., Angel J. B., McMahon D., Ho D., Devanarayan V., Rode R., Salgo M. P., Kempf D. J., Granneman R., Leonard J. M., Sun E., Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999 13 2 213 224 2-s2.0-0032971472 10.1097/00002030- 199902040-00009 (Pubitemid 29050409)
7. Hall C. S., Raines C. P., Barnett S. H., Moore R. D., Gallant J. E., Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens. AIDS 1999 13 10 1207 1212 2-s2.0-0032792127 10.1097/00002030-199907090-00009 (Pubitemid 29361090)
8. Lallemand F., Adda N., Schneider V., Jacomet C., Salhi Y., Rozenbaum W., Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination. Clinical Infectious Diseases 1999 28 5 1184 1185 2-s2.0-0032909370 (Pubitemid 29203576)
9. Miller V., Sabin C., Hertogs K., Bloor S., Martinez-Picado J., D'Aquila R., Larder B., Lutz T., Gute P., Weidmann E., Rabenau H., Phillips A., Staszewski S., Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000 14 18 2857 2867 2-s2.0-0034523865 10.1097/00002030-200012220-00007 (Pubitemid 32042749)
10. Lawrence J., Hullsiek K. Huppler, Thackeray L. M., Abrams D. I., Crane L. R., Mayers D. L., Jones M. C., Saldanha J. M., Schmetter B. S., Baxter J. D., Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study. Journal of Acquired Immune Deficiency Syndromes 2006 43 2 169 178 2-s2.0-33749036548 10.1097/01.qai.0000242450.74779.ee (Pubitemid 44454810)
11. Miller V., Cozzi-Lepri A., Hertogs K., Gute P., Larder B., Bloor S., Klauke S., Rabenau H., Phillips A., Staszewski S., HIV drug susceptibility and treatment response to mega-HAART regimens in patients from the Frankfurt HIV cohort. Antiviral Therapy 2000 5 1 49 55 2-s2.0-17544379494 (Pubitemid 30261206)
12. Montaner J. S. G., Harrigan P. R., Jahnke N., Raboud J., Castillo E., Hogg R. S., Yip B., Harris M., Montessori V., O'Shaughnessy M. V., Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 2001 15 1 61 69 2-s2.0-0035808534 10.1097/00002030- 200101050-00010 (Pubitemid 32055780)
13. Katlama C., Dominguez S., Gourlain K., Duvivier C., Delaugerre C., Legrand M., Tubiana R., Reynes J., Molina J. M., Peytavin G., Calvez V., Costagliola D., Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004 18 2 217 226 2-s2.0-10744223335 10.1097/00002030-200401230-00011 (Pubitemid 38253444)
14. Lalezari J. P., Henry K., O'Hearn M., Montaner J. S. G., Piliero P. J., Trottier B., Walmsley S., Cohen C., Kuritzkes D. R., Eron J. J., Chung J., DeMasi R., Donatacci L., Drobnes C., Delehanty J., Salgo M., Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. The New England Journal of Medicine 2003 348 22 2175 2185 2-s2.0-0038576281 10.1056/NEJMoa035026 (Pubitemid 36618128)
15. Lazzarin A., Clotet B., Cooper D., Reynes J., Arastéh K., Nelson M., Katlama C., Stellbrink H. J., Delfraissy J. F., Lange J., Huson L., DeMasi R., Wat C., Delehanty J., Drobnes C., Salgo M., Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. The New England Journal of Medicine 2003 348 22 2186 2195 2-s2.0-0037849954 10.1056/NEJMoa035211 (Pubitemid 36618129)
16. Nelson M., Arastéh K., Clotet B., Cooper D. A., Henry K., Katlama C., Lalezari J. P., Lazzarin A., Montaner J. S. G., O'Hearn M., Piliero P. J., Reynes J., Trottier B., Walmsley S. L., Cohen C., Eron J. J., Kuritzkes D. R., Lange J., Stellbrink H. J., Delfraissy J. F., Buss N. E., Donatacci L., Wat C., Smiley L., Wilkinson M., Valentine A., Guimaraes D., DeMasi R., Chung J., Salgo M. P., Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. Journal of Acquired Immune Deficiency Syndromes 2005 40 4 404 412 2-s2.0-27944473910 10.1097/01.qai. 0000185314.56556.c3 (Pubitemid 41669173)
17. Harris M., Harrigan P. R., Montaner J. S. G., Volberding P. A., Sande M. A., Lange J., Greene W. C., Gallant J. E., Chapter 46: Antiretroviral Therapy of Drug-resistant HIV. Global HIV/AIDS Medicine 2007 Saunders Elsevier
18. Steinbrook R., HIV infection-a new drug and new costs. The New England Journal of Medicine 2003 348 22 2171 2172 2-s2.0-0038476114 10.1056/NEJMp030043 (Pubitemid 36618126)
19. Tashima K. T., Carpenter C. C. J., Fusion inhibition-a major but costly step forward in the treatment of HIV-1. The New England Journal of Medicine 2003 348 22 2249 2250 2-s2.0-0037799388 10.1056/NEJMe030042 (Pubitemid 36618137)
20. Bureau of Labor and Statistics. Consumer price index-medical care component, http://www.bls.gov/cpi/
21. Drug Topics Red Book 2001 Montvale, NJ, USA Medical Economics
22. Pham P. A., Drug profile: fosamprenavir (Lexiva). The Hopkins HIV Report 2003 15 6 10 11
23. Montaner J., Guimaraes D., Chung J., Gafoor Z., Salgo M., DeMasi R., Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clinical Trials 2005 6 6 281 290 2-s2.0-33644746624 10.1310/0XH7-F2V2-1K0R-NU2W (Pubitemid 43336962)
24. Drug Topics Red Book 2004 Montvale, NJ, USA Medical Economics
25. Sax P. E., Losina E., Weinstein M. C., Paltiel A. D., Goldie S. J., Muccio T. M., Kimmel A. D., Zhang H., Freedberg K. A., Walensky R. P., Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. Journal of Acquired Immune Deficiency Syndromes 2005 39 1 69 77 2-s2.0-20944433124 10.1097/01.qai.0000160406.08924.a2 (Pubitemid 40617021)
26. Hornberger J., Kilby J. M., Wintfeld N., Green J., Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. AIDS Research and Human Retroviruses 2006 22 3 240 247 2-s2.0-33645377251 10.1089/aid.2006.22.240
27. World Health Organization. Choosing interventions that are cost-effective (WHOCHOICE): cost-effectiveness thresholds, http://www.who.int/choice/costs/ CER-thresholds/en/index.html
28. International Monetary Fund, World Economic Outlook Database 2008 Washington, DC, USA International Monetary Fund. http://www.imf.org/external/ pubs/ft/weo/2008/01/weodata/weorept.aspx?sy=2008&ey=2008&scsm=1&ssd= 1&sort=country
29. Trottier B., Walmsley S., Reynes J., Piliero P., O'Hearn M., Nelson M., Montaner J., Lazzarin A., Lalezari J., Katlama C., Henry K., Cooper D., Clotet B., Arastéh K., Delfraissy J. F., Stellbrink H. J., Lange J., Kuritzkes D., Eron J. J., Cohen C., Kinchelow T., Bertasso A., Labriola-Tompkins E., Shikhman A., Atkins B., Bourdeau L., Natale C., Hughes F., Chung J., Guimaraes D., Drobnes C., Bader-Weder S., DeMasi R., Smiley L., Salgo M. P., Buss N., Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. Journal of Acquired Immune Deficiency Syndromes 2005 40 4 413 421 2-s2.0-27944453927 10.1097/01.qai.0000185313.48933.2c (Pubitemid 41669174)
30. Harris M., Joy R., Larsen G., Valyi M., Walker E., Frick L. W., Palmatier R. M., Wring S. A., Montaner J. S. G., Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS 2006 20 5 719 723 2-s2.0-33745095614 10.1016/j.athoracsur.2005.12.029
31. Hicks C. B., Cahn P., Cooper D. A., Walmsley S. L., Katlama C., Clotet B., Lazzarin A., Johnson M. A., Neubacher D., Mayers D., Valdez H., Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. The Lancet 2006 368 9534 466 475 2-s2.0-33746576313 10.1016/S0140-6736(06)69154-X (Pubitemid 44142769)
32. Clotet B., Bellos N., Molina J. M., Cooper D., Goffard J. C., Lazzarin A., Wöhrmann A., Katlama C., Wilkin T., Haubrich R., Cohen C., Farthing C., Jayaweera D., Markowitz M., Ruane P., Spinosa-Guzman S., Lefebvre E., Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. The Lancet 2007 369 9568 1169 1178 2-s2.0-34047207229 10.1016/S0140-6736(07)60497-8 (Pubitemid 46541620)
33. Madruga J. V., Cahn P., Grinsztejn B., Haubrich R., Lalezari J., Mills A., Pialoux G., Wilkin T., Peeters M., Vingerhoets J., de Smedt G., Leopold L., Trefiglio R., Woodfall B., Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet 2007 370 9581 29 38 2-s2.0-34347327010 10.1016/S0140-6736(07)61047-2 (Pubitemid 47017466)
34. Lazzarin A., Campbell T., Clotet B., Johnson M., Katlama C., Moll A., Towner W., Trottier B., Peeters M., Vingerhoets J., de Smedt G., Baeten B., Beets G., Sinha R., Woodfall B., Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet 2007 370 9581 39 48 2-s2.0-34347354196 10.1016/S0140-6736(07)61048-4 (Pubitemid 47017467)
35. Gulick R. M., Lalezari J., Goodrich J., Clumeck N., Dejesus E., Horban A., Nadler J., Clotet B., Karlsson A., Wohlfeiler M., Montana J. B., McHale M., Sullivan J., Ridgway C., Felstead S., Dunne M. W., Van Der Ryst E., Mayer H., Maraviroc for previously treated patients with R5 HIV-1 infection. The New England Journal of Medicine 2008 359 14 1429 1441 2-s2.0-54849146700 10.1056/NEJMoa0803152
36. Steigbigel R. T., Cooper D. A., Kumar P. N., Eron J. E., Schechter M., Markowitz M., Loutfy M. R., Lennox J. L., Gatell J. M., Rockstroh J. K., Katlama C., Yeni P., Lazzarin A., Clotet B., Zhao J., Chen J., Ryan D. M., Rhodes R. R., Killar J. A., Gilde L. R., Strohmaier K. M., Meibohm A. R., Miller M. D., Hazuda D. J., Nessly M. L., DiNubile M. J., Isaacs R. D., Nguyen B. Y., Teppler H., Raltegravir with optimized background therapy for resistant HIV-1 infection. The New England Journal of Medicine 2008 359 4 339 354 2-s2.0-47949120697 10.1056/NEJMoa0708975
37. Katlama C., Esposito R., Gatell J. M., Goffard J. C., Grinsztejn B., Pozniak A., Rockstroh J., Stoehr A., Vetter N., Yeni P., Parys W., Vangeneugden T., Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-Week results of POWER 1. AIDS 2007 21 4 395 402 2-s2.0-33847041109 10.1097/QAD.0b013e328013d9d7
38. Haubrich R., Berger D., Chiliade P., Colson A., Conant M., Gallant J., Wilkin T., Nadler J., Pierone G., Saag M., Van Baelen B., Lefebvre E., Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007 21 6 F11 F18 2-s2.0-34047205841 10.1097/QAD.0b013e3280b07b47 (Pubitemid 46568621)
39. Katlama C., Haubrich R., Lalezari J., Lazzarin A., Madruga J. V., Molina J. M., Schechter M., Peeters M., Picchio G., Vingerhoets J., Woodfall B., De Smedt G., Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009 23 17 2289 2300 2-s2.0-70449368908 10.1097/QAD.0b013e3283316a5e
40. Hubben G. A. A., Bos J. M., Veltman-Starkenburg C. A., Stegmeijer S., Finnern H. W., Kappelhoff B. S., Simpson K. N., Tramarin A., Postma M. J., Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Cost Effectiveness and Resource Allocation 2007 5, article 15 2-s2.0-38849169931 10.1186/1478-7547-5-15 (Pubitemid 351187412)
41. Simpson K. N., Roberts G., Hicks C. B., Finnern H. W., Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clinical Trials 2008 9 4 225 237 2-s2.0-51949119174 10.1310/hct0904-225
42. Chan-Tack K. M., Struble K. A., Birnkrant D. B., Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's adverse event reporting system. AIDS Patient Care and STDs 2008 22 11 843 850 2-s2.0-56749184934 10.1089/apc.2008.0043
43. Madruga J. V., Berger D., McMurchie M., Suter F., Banhegyi D., Ruxrungtham K., Norris D., Lefebvre E., de Béthune M. P., Tomaka F., De Pauw M., Vangeneugden T., Spinosa-Guzman S., Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. The Lancet 2007 370 9581 49 58 2-s2.0-34347329093 10.1016/S0140-6736(07)61049-6 (Pubitemid 47023100)
44. Mauskopf J., Annemans L., Hill A. M., Smets E., A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection. PharmacoEconomics 2010 28 1 1 16 2-s2.0-78650731033
45. Ribera E., Curran A., Double-boosted protease inhibitor antiretroviral regimens: what role? Drugs 2008 68 16 2257 2267 2-s2.0-55149115684
46. Hammer S. M., Vaida F., Bennett K. K., Holohan M. K., Sheiner L., Eron J. J., Wheat L. J., Mitsuyasu R. T., Gulick R. M., Valentine F. T., Aberg J. A., Rogers M. D., Karol C. N., Saah A. J., Lewis R. H., Bessen L. J., Brosgart C., DeGruttola V., Mellors J. W., Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002 288 2 169 180 2-s2.0-0037055027 (Pubitemid 34755277)
47. Cohen C., Liporace R., de Jesus E.,.Use of twice-daily darunavir as a substitution for dual-boosted PIs in virologically suppressed patients: primary endpoint results of a pilot randomized clinical trial. Proceedings of the 12th European AIDS Conference November 2009 Cologne, Germany. Abstract PS4/2
48. Harris M., Hull M., Ochoa P., Toulson A., Montaner J., Immediate vs. deferred substitution of dual boosted protease inhibitors (PIs) with darunavir/ritonavir (DRV/r). Canadian Journal of Infectious Diseases & Medical Microbiology 2009 20 supplement B, p. 16B, Abstract O013
49. Johnson V. A., Calvez V., Günthard H. F., Paredes R., Pillay D., Shafer R., Wensing A. M., Richman D. D., 2011 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine 2011 19 4 156 164 2-s2.0-79952267805
50. Wilkin T. J., Su Z., Kuritzkes D. R., Hughes M., Flexner C., Gross R., Coakley E., Greaves W., Godfrey C., Skolnik P. R., Timpone J., Rodriguez B., Gulick R. M., HIV type 1 chemokine coreceptor use among antiretroviral- experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clinical Infectious Diseases 2007 44 4 591 595 2-s2.0-33846932573 10.1086/511035 (Pubitemid 46233265)
51. Moreno S., González J., Lekander I., Martí B., Oyagüez I., Sánchez-de la Rosa R., Casado M. A., Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system. Clinical Therapeutics 2010 32 13 2232 2245 2-s2.0-79951523962 10.1016/S0149-2918(10) 80026-8
52. Contreras-Hernandez I., Becker D., Chancellor J., Kühne F., Mould-Quevedo J., Vega G., Marfatia S., Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico. Value in Health 2010 13 8 903 914 2-s2.0-78650076966 10.1111/j.1524-4733.2010.00798.x
53. Kühne F., Chancellor J., Mollon P., Myers D., Louie M., Powderly W., A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. HIV Clinical Trials 2010 11 2 80 99 2-s2.0-77953571602 10.1310/hct1102-80
54. Harris M., Raltegravir: its use in the treatment of HIV infection. Clinical Medicine: Therapeutics 2009 1 183 197
55. Chaudhary M. A., Moreno S., Kumar R. N., Nocea G., Elbasha E., Cost-effectiveness analysis of raltegravir in treatment-experienced HIV type 1-infected patients in Spain. AIDS Research and Human Retroviruses 2009 25 7 679 689 2-s2.0-70349216963 10.1089/aid.2008.0254
56. Elbasha E. E., Szucs T., Chaudhary M. A., Kumar R. N., Roediger A., Cook J. R., Opravil M., Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clinical Trials 2009 10 4 233 253 2-s2.0-70349141758 10.1310/hct1004-233
57. Harris M., Larsen G., Montaner J. S. G., Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008 22 10 1224 1226 2-s2.0-50949112147 10.1097/QAD.0b013e328302f3b5
58. De Castro N., Braun J., Charreau I., Pialoux G., Cotte L., Katlama C., Raffi F., Weiss L., Meynard J. L., Yazdanpanah Y., Delaugerre C., Madelaine-Chambrin I., Aboulker J. P., Molina J. M., Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clinical Infectious Diseases 2009 49 8 1259 1267 2-s2.0-70349902494 10.1086/605674
59. Towner W., Klein D., Kerrigan H. L., Follansbee S., Yu K., Horberg M., Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-Week results of the CHEER study. Journal of Acquired Immune Deficiency Syndromes 2009 51 4 367 373 2-s2.0-68049148420 10.1097/QAI.0b013e3181ae35de
60. Santos J. R., Llibre J. M., Ferrer E., Domingo P., Imaz A., Moltó J., Martin-Iguacel R., Caum C., Podzamczer D., Clotet B., Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. HIV Clinical Trials 2009 10 6 432 438 2-s2.0-76749156296 10.1310/hct1006-432
61. Hill A. M., Cho M., Mrus J. M., The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients. AIDS Reviews 2011 13 1 41 48 2-s2.0-79960623402
62. Yazdanpanah Y., Fagard C., Descamps D., Taburet A. M., Colin C., Roquebert B., Katlama C., Pialoux G., Jacomet C., Piketty C., Bollens D., Molina J. M., Chěne G., High rate of virologic suppression with raltegravir plus etravirine and darunavir/ ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clinical Infectious Diseases 2009 49 9 1441 1449 2-s2.0-72849119170 10.1086/630210
63. Imaz A., del Saz S. Villar, Ribas M. A., Curran A., Caballero E., Falcó V., Crespo M., Ocaña I., Diaz M., De Gopegui E. R., Riera M., Ribera E., Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 2009 52 3 382 386 2-s2.0-71049149300 10.1097/QAI.0b013e3181b17f53
64. Kozal M. J., Drug-resistant human immunodefiency virus. Clinical Microbiology and Infection 2009 15 supplement s1 69 73 2-s2.0-59649092052 10.1111/j.1469-0691.2008.02687.x
65. Brenner B. G., Routy J. P., Petrella M., Moisi D., Oliveira M., Detorio M., Spira B., Essabag V., Conway B., Lalonde R., Sekaly R. P., Wainberg M. A., Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. Journal of Virology 2002 76 4 1753 1761 2-s2.0-0036149707 10.1128/JVI.76.4.1753-1761.2002 (Pubitemid 34094622)
66. Gill V. S., Lima V. D., Zhang W., Wynhoven B., Yip B., Hogg R. S., Montaner J. S. G., Harrigan P. R., Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clinical Infectious Diseases 2010 50 1 98 105 2-s2.0-72049086981 10.1086/648729
67. Edurant (rilpivirine) Tablets; Full Prescribing Information. Tibotec, Inc. 2011
68. Zolopa A. R., Berger D. S., Lampiris H., Zhong L., Chuck S. L., Enejosa J. V., Kearney B. P., Cheng A. K., Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. Journal of Infectious Diseases 2010 201 6 814 822 2-s2.0-77749267991 10.1086/650698
69. Eron J., Kumar P., Lazzarin A., DTG in subjects with HIV exhibiting RAL resistance: functional monotherapy results of VIKING study cohort II. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections (CROI '11) February 2011 Boston, Mass, USA. Abstract 151LB
70. Garrido C., Villacian J., Zahonero N., Pattery T., Garcia F., Gutierrez F., Caballero E., Van Houtte M., Soriano V., De Mendoza C., Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrobial Agents and Chemotherapy 2012 56 6 2873 2878 2-s2.0-84861136225 10.1128/AAC.06170-11
71. Eron J. J., Young B., Cooper D. A., Youle M., DeJesus E., Andrade-Villanueva J., Workman C., Zajdenverg R., Fätkenheuer G., Berger D. S., Kumar P. N., Rodgers A. J., Shaughnessy M. A., Walker M. L., Barnard R. J., Miller M. D., DiNubile M. J., Nguyen B. Y., Leavitt R., Xu X., Sklar P., Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir- based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. The Lancet 2010 375 9712 396 407 2-s2.0-75149175071 10.1016/S0140- 6736(09)62041-9
72. Baldanti F., Paolucci S., Gulminetti R., Brandolini M., Barbarini G., Maserati R., Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens. Journal of Medical Virology 2010 82 1 116 122 2-s2.0-74849093213 10.1002/jmv.21651
73. Hawkins C., Murphy R. L., Management of antiretroviral failure and resistance in developing countries. Current Opinion in HIV and AIDS 2009 4 6 538 544 2-s2.0-70350159352 10.1097/COH.0b013e328331d2fb
74. Montaner J. S., Hogg R., Wood E., Kerr T., Tyndall M., Levy A. R., Harrigan P. R., The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. The Lancet 2006 368 9534 531 536 2-s2.0-33746512140 10.1016/S0140-6736(06)69162-9 (Pubitemid 44142776)
75. Montaner J. S., Lima V. D., Barrios R., Yip B., Wood E., Kerr T., Shannon K., Harrigan P. R., Hogg R. S., Daly P., Kendall P., Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. The Lancet 2010 376 9740 532 539 2-s2.0-77956056661 10.1016/S0140-6736(10)60936-1
76. Montaner J. S., Treatment as prevention-a double hat-trick. The Lancet 2011 378 9787 208 209 2-s2.0-79960980228 10.1016/S0140-6736(11)60821-0
77. Cohen M. S., Chen Y. Q., McCauley M., Gamble T., Hosseinipour M. C., Kumarasamy N., Hakim J. G., Kumwenda J., Grinsztejn B., Pilotto J. H. S., Godbole S. V., Mehendale S., Chariyalertsak S., Santos B. R., Mayer K. H., Hoffman I. F., Eshleman S. H., Piwowar-Manning E., Wang L., Makhema J., Mills L. A., De Bruyn G., Sanne I., Eron J., Gallant J., Havlir D., Swindells S., Ribaudo H., Elharrar V., Burns D., Taha T. E., Nielsen-Saines K., Celentano D., Essex M., Fleming T. R., Prevention of HIV-1 infection with early antiretroviral therapy. The New England Journal of Medicine 2011 365 6 493 505 2-s2.0-84864417531 10.1056/NEJMoa1105243